PCM
EPZM

Prelude Capital Management’s Epizyme, Inc EPZM Stock Holding History

Prelude Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,000
Closed -$19K – 2147
2015
Q1 		$19K Hold
1,000
– – ﹤0.01% 1758
2014
Q4 		$19K Buy
+1,000
New +$23.4K ﹤0.01% 1749
2014
Q2 		– Sell
-500
Closed -$11K – 2252
2014
Q1 		$11K Buy
+500
New +$15.2K ﹤0.01% 1759

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Prelude Capital Management's EPZM Position: Q3 2020 in Review

Prelude Capital Management sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 20,812 shares — an estimated $334K sold.

Prelude Capital Management first reported a position in EPZM in Q1 2014 and held it in 15 quarters. The position peaked at $912K in Q2 2019. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Prelude Capital Management reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 20,812 Epizyme, Inc shares in Q3 2020, an estimated $334K.
  • Prelude Capital Management first reported a position in Epizyme, Inc in Q1 2014 and held it in 15 quarters.
  • Prelude Capital Management's Epizyme, Inc position peaked at $912K in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.